Among the 5 liver cancer cell lines used in this study, 3 cell lines have oncogenic alterations known to activate the RAS/MAPK pathway (Huh7 and SNU387 with FGF19 amplifications; HepG2 with NRAS mutation) (41). Here, FGF19 is linked to liver cancer.